Cell Death Research & Therapy Unit, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Leuven, Belgium.
Cytokine Growth Factor Rev. 2013 Aug;24(4):319-33. doi: 10.1016/j.cytogfr.2013.01.005. Epub 2013 Feb 5.
Recently, cytokine-based pro-tumourigenic signalling has been found to play a major role in the immune system's pro-tumourigenic activity. On the other hand, other recent findings have shown that immunogenic cancer cell death triggered by certain anticancer modalities might reset the dysfunctional immune system towards the activation of a long-lasting protective anti-tumour response. Therefore, using inducers of immunogenic cell death (ICD) that can prevent or impede tumour-promoting cytokine signalling is one of the best ways of instigating or restoring efficient anti-tumour immunity. In this review it is discussed, how the different ICD inducers interact with the immune system and influence cytokine-based pro-tumourigenic signalling. We believe that it is crucial to discover or develop new anti-cancer therapeutic modalities that can induce ICD and impede tumour-promoting cytokine signalling.
最近,基于细胞因子的促肿瘤发生信号在免疫系统的促肿瘤发生活性中发挥了主要作用。另一方面,最近的其他发现表明,某些抗癌方式引发的免疫原性癌细胞死亡可能会重置功能失调的免疫系统,使其向激活持久的抗肿瘤反应转变。因此,使用能够预防或阻碍促肿瘤细胞因子信号的免疫原性细胞死亡(ICD)诱导剂是引发或恢复有效抗肿瘤免疫的最佳方法之一。在这篇综述中,讨论了不同的 ICD 诱导剂如何与免疫系统相互作用并影响基于细胞因子的促肿瘤发生信号。我们认为,发现或开发能够诱导 ICD 并阻碍促肿瘤细胞因子信号的新抗癌治疗方法至关重要。